The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2024 | ABC-07 : chemotherapy with or without SBRT in cholangiocarcinoma
Laura Williams Goff, MD, MSCI, MMHC, Vanderbilt-Ingram Cancer Center, Nashville, TN, discusses the randomized ABC-07 trial (ISRCTN10639376) of gemcitabine plus cisplatin alone versus gemcitabine plus cisplatin followed by stereotactic body radiation therapy (SBRT) in liver-limited cholangiocarcinoma. Analysis of progression-free survival (PFS) and overall survival (OS) revealed that the PFS was slightly worse in the SBRT arm, while OS was essentially the same in both treatment groups, as indicated by the collected hazard ratios. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consulting or Advisory Role – Athenum Consulting; Boehringer Ingelheim; Cardinal Health; Exelixis; QED Therapeutics; Relay Therapeutics
Research Funding – Agios (Inst); ASLAN Pharmaceuticals (Inst); Basilea (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Merck (Inst)
